--- title: "Enanta Pharmaceuticals Metrics Guide" description: "Enanta Pharmaceuticals Inc. revenue, margins, cash flow and balance sheet figures by fiscal year, taken from its SEC filings, with the ratios explained." canonical: https://www.getswoopr.com/stocks/companies/enanta-pharmaceuticals-inc/financial-metrics/ source: "Swoopr Investment: https://www.getswoopr.com" --- # Enanta Pharmaceuticals Inc. Financial Metrics Guide ## Direct Answer > Enanta Pharmaceuticals Inc. reported revenue of $65 million for the fiscal year ended September 30, 2025, with an operating margin of -130.7% and net income of -$82 million, according to its SEC filings. Revenue fell 3.4% from the prior year. ## What Are Enanta Pharmaceuticals Inc.'s Key Financial Figures? | Fiscal year | FY2025ended September 30, 2025 | FY2024ended September 30, 2024 | FY2023ended September 30, 2023 | FY2022ended September 30, 2022 | | --- | --- | --- | --- | --- | | Revenue | $65 million | $68 million | $79 million | $86 million | | Operating income | -$85 million | -$122 million | -$137 million | -$124 million | | Operating margin | -130.7% | -179.9% | -173.2% | -143.7% | | Net income | -$82 million | -$116 million | -$134 million | -$122 million | | Net margin | -125.4% | -171.6% | -169.0% | -141.3% | | Operating cash flow | -$19 million | -$79 million | -$103 million | -$85 million | | Capital expenditures | $13 million | $18 million | $9 million | $2 million | | Free cash flow | -$32 million | -$97 million | -$112 million | -$87 million | Operating margin widened by 49.3 percentage points between fiscal 2024 and 2025, which separates pricing and cost discipline from revenue growth alone. Free cash flow (operating cash flow minus capital expenditures) was -$32 million against net income of -$82 million; cash generation covered reported earnings. ![Bar chart of Enanta Pharmaceuticals Inc. revenue, operating income, net income for fiscal 2022 to 2025. In fiscal 2025, revenue was $65 million, operating income negative $85 million and net income negative $82 million.](https://www.getswoopr.com/images/charts/enanta-pharmaceuticals-inc-metrics-revenue-profit.webp) *Enanta Pharmaceuticals Inc. revenue, operating income and net income by fiscal year, from the figures in the table above. Select the chart to open it full size.* ![Line chart of Enanta Pharmaceuticals Inc. operating margin and net margin for fiscal 2022 to 2025. In fiscal 2025, operating margin was -130.7% and net margin was -125.4%.](https://www.getswoopr.com/images/charts/enanta-pharmaceuticals-inc-metrics-margins.webp) *Enanta Pharmaceuticals Inc. operating margin and net margin by fiscal year: operating income and net income as a share of revenue. Select the chart to open it full size.* ![Bar chart of Enanta Pharmaceuticals Inc. operating cash flow, capital expenditures, free cash flow for fiscal 2022 to 2025. In fiscal 2025, operating cash flow was negative $19 million, capital expenditures was $13 million, free cash flow was negative $32 million.](https://www.getswoopr.com/images/charts/enanta-pharmaceuticals-inc-metrics-cash-flow.webp) *Enanta Pharmaceuticals Inc. operating cash flow, capital expenditures and free cash flow by fiscal year. Select the chart to open it full size.* ## What Does Enanta Pharmaceuticals Inc.'s Balance Sheet Show? | Cash and cash equivalents | $32 million | | --- | --- | | Long-term debt | Not reported | | Total assets | $281 million | | Total liabilities | $216 million | | Shareholders' equity | $65 million | | Current ratio | 4.2x | Balance sheet values are as of the end of fiscal 2025. Income statement figures describe a whole year; balance sheet figures describe a single day, so the two answer different questions. ## Where These Numbers Come From Every figure on this page is a value Enanta Pharmaceuticals Inc. reported in its own SEC filings, read from the SEC's XBRL data (accession 0001193125-25-288121 for fiscal year 2025). Ratios are computed from those reported values. Figures were retrieved on October 7, 2026; a later amendment or a new annual report can change them, and the filing itself always takes precedence over this summary. Each fiscal year is labeled by the calendar year in which it ended, so a company that names the same period differently in its own filings (many retailers whose year ends in January) may use another label. A year is left out of the table when the SEC data set holds no value for it. A figure shown as "Not reported" means the company did not file a value under the standard tag Swoopr reads, not that the amount was zero. This page is educational and describes reported history only; it is not a forecast or a recommendation. ## Frequently Asked Questions ### What was Enanta Pharmaceuticals Inc.'s revenue in fiscal 2025? Enanta Pharmaceuticals Inc. reported revenue of $65 million for the fiscal year ended September 30, 2025, according to its SEC filings. ### What is Enanta Pharmaceuticals Inc.'s operating margin? Enanta Pharmaceuticals Inc.'s operating margin was -130.7% in fiscal 2025: operating income of -$85 million on revenue of $65 million. ### How much free cash flow did Enanta Pharmaceuticals Inc. generate? Operating cash flow of -$19 million less capital expenditures of $13 million gives free cash flow of -$32 million for fiscal 2025. ## References - [SEC EDGAR: ENANTA PHARMACEUTICALS INC Form 10-K filed November 19, 2025](https://www.sec.gov/Archives/edgar/data/1177648/000119312525288121/enta-20250930.htm) - [SEC EDGAR: ENANTA PHARMACEUTICALS INC annual and quarterly filings](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=1177648&type=10-K) - [SEC: EDGAR application programming interfaces (XBRL frames and submissions data)](https://www.sec.gov/search-filings/edgar-application-programming-interfaces) ## Related Pages - [Enanta Pharmaceuticals Inc. company dossier](https://www.getswoopr.com/stocks/companies/enanta-pharmaceuticals-inc/) - [Enanta Pharmaceuticals Inc. financial metrics](https://www.getswoopr.com/stocks/companies/enanta-pharmaceuticals-inc/financial-metrics/) - [Enanta Pharmaceuticals Inc. financial risk indicators](https://www.getswoopr.com/stocks/companies/enanta-pharmaceuticals-inc/risks-monitoring/) - [Enanta Pharmaceuticals Inc. business model and revenue mix](https://www.getswoopr.com/stocks/companies/enanta-pharmaceuticals-inc/business-model/) - [Fundamental analysis guides](https://www.getswoopr.com/learn/fundamental-analysis/) [Swoopr Editorial Team](https://www.getswoopr.com/authors/swoopr-editorial-team/) Swoopr's editorial team produces independent investment education content. Content is for educational purposes only and does not constitute personalized investment advice. See our [editorial policy](https://www.getswoopr.com/legal/editorial-policy/) and [corrections policy](https://www.getswoopr.com/legal/corrections-policy/).